This article highlights the regulatory and legal aspects of the information that is provided to health care practitioners and consumers by medical communications/drug information departments within the pharmaceutical industry. The legal and regulatory basis for pharmaceutical industry drug information centers (PIDICs) is presented. Then management of regulatory and legal issues by PIDICs is discussed, focusing on avoiding or minimizing risks through due diligence, prudence, and active quality control.
KesslerDAPinesWLThe federal regulation of prescription drag advertising and promotion. JAMA.1990;264:2409–2415.
3.
TaylorMR“Drug regulation, off-label uses and CME-Reconciling competing values,”Food and Drug Law Institute Seminar on Drug Advertising and Promotion, Arlington, VA, February 26, 1992.
Anonymous. Guidance for Industry—Industry-Supported Scientific and Educational Activities. Federal Register.1997(Dec. 3);62(232):64093–64100.
6.
Anonymous. 21 CFR Parts 16 and 99—Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices; Final Rule. Federal Register.1998(Nov. 20);63(224):64555–64588.
7.
US Food and Drug Administration. Drug Company Supported Activities in Scientific or Educational Contexts. Draft Paper #1. Rockville, MD: US Food and Drug Administration; October 26, 1991.
8.
SylvanLPalmer-ShevlinN.Bristol-Myers Squibb Drug Information Department services. Hosp Pharm.1995;30:38–39, 41.
9.
EvensRPThe state of the art, and future directions of drug information centers. Pharmacy Intnl.1985; 6:74–77.
10.
ClarkTTWhiteBDHamnerMEPharmacy Law. Liability of drug information centers. US Pharmacist.1982;7:39–56.
